Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17544899 | 0.98 | CA9 (0.71) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL31231828 | 0.89 | CA9 (0.59) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL519951 | 0.89 | CA9 (0.59) | CA9NPC1MAPK13MAPK12MAPK11 | |
| Methane SCHEMBL28577463 | 0.87 | CA9 (0.57) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL4594845 | 0.86 | KIF11 (0.68) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29370621 | 0.85 | CA9 (1.00) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL521524 | 0.85 | CA9 (1.00) | CA9NPC1MAPK13MAPK12MAPK11 | |
| 4-Aminophenol SCHEMBL7014541 | 0.83 | CA9 (0.57) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL22660 | 0.82 | AHR (0.61) | CA9CYP11B1CYP11B2PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL15206761 | 0.81 | AHR (0.59) | CA9CYP11B1CYP11B2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | US | claimed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| JP-2003508387-A | — | — | 2003-03-04 | — | — | JP | claimed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | claimed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | claimed |
| JP-54044678-A | — | — | None | — | — | JP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-0145010-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-14 | — | — | EP | disclosed |
| EP-0275888-A2 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | Roche Diagnostics GmbH (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4593035-A | FOR TREATING HEART DISEASE | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1986-06-03 | — | — | US | disclosed |
| EP-0145010-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
| JP-S5444678-A | 3,4-DIHYDROCARBOSTYRIL DERIVATIVE | OTSUKA PHARMACEUT CO LTD | 1979-04-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | CA9 3887/4885NPC1 3988/4885MAPK13 1068/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CA9 4602/4885NPC1 1672/4885MAPK13 3725/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | CA9 2561/4885NPC1 4644/4885MAPK13 2219/4885 |
| US-20110105472-A1 | Diaminopyrimidines as crop protection agents | DDX41, DDX1, DDX5 | CA9 1421/4885NPC1 4614/4885MAPK13 2880/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | CA9 2303/4885NPC1 2502/4885MAPK13 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.